Excitement is building as the world’s first vaccine for ovarian cancer is being developed by researchers at the University of Oxford.
The hope is that the jab, named OvarianVax, could be given to women preventatively on the NHS with the aim of eliminating the disease.
The study is being conducted by Professor Ahmed Ahmed, director of the ovarian cancer cell laboratory at MRC Weatherall Institute of Molecular Medicine, University of Oxford, and his team, whose purpose is to identify cellular targets for the vaccine.
Here is what we know so far about the vaccine.
How does the vaccine work, and what symptoms should we look out for?
“The vaccine will teach the immune system to recognise proteins called tumour associated antigens, which appear on the surface of cells that are becoming cancerous,” said Dr David Crosby, head of prevention and early detection research at Cancer Research UK.
“Once the immune system has been primed by the vaccine to recognise these antigens, the white blood cells will then be able to more effectively find and kill the cells which could go on to form tumours.
READ MORE: Parking scheme 'disaster' for Oxford school - head says
“In this study, scientists will find out which proteins on the surface of early-stage ovarian cancer cells are most strongly recognised by the immune system, and how effectively the vaccine stimulates immune cells to kill mini-models of ovarian cancer, called organoids."
When will the vaccine be ready?
“It will take many years for the vaccine to go through clinical trials before it is ready for wider use,” said Dr Crosby.
“At this stage, scientists are testing the best components to include in the vaccine, by first trialling it in the lab with samples taken from ovarian cancer patients.”
“It will take many years for the vaccine to go through clinical trials before it is ready for wider use,” said Dr Crosby.
“At this stage, scientists are testing the best components to include in the vaccine, by first trialling it in the lab with samples taken from ovarian cancer patients.”
Who will be eligible for the vaccine?
“Clinical trials will be required to establish which women will benefit most from the vaccine and it will take many years for the vaccine to go through those trials before it is ready for wider use,” said Dr Crosby.
“It is likely that, at least initially, the vaccine would be used in women at higher than average risk of developing ovarian cancer.
“However, the funding for this research is an exciting step towards a world where doctors can prevent ovarian cancer at an early stage, rather than treating it once the disease has already taken hold.”
What are the symptoms?
“Ovarian cancer is notorious for causing very minimal symptoms in the early stages, and symptoms can be non-specific, such as abdominal distension and bloating that doesn’t come and go, a new onset of abdominal and pelvic pain that you feel most days, nausea, and fullness,” said Mr Saurabh Phadnis, consultant gynaecologist and gynaecological oncologist at London Gynaecology.
READ MORE: Police 'very concerned' about woman, 67, missing from Oxford
“Also, urinary frequency and changes in bowel habits, a loss of appetite and weight, and any lower abdominal lumps.
“Because these symptoms are so non-specific, being aware and alert to changes in the body is essential. If you have any of these symptoms that are persistent you should seek immediate medical help with your GP.”
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here